XGX Pharma ApS: Financial statements 2024
CVR: 32289290
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
XGX Pharma ApS (CVR 32289290) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 16,033,793 and a net result of DKK 4,453,433 compared with DKK 460,891 the year before. That is an increase of 97.9% compared with the year before. Equity in the 2024 report amounted to DKK 18,713,061. The solvency ratio was 48%. The company had 4 employees in the financial year.
- Gross Profit
- DKK 16,033,793
- Profit/Loss
- DKK 4,453,433
- Equity
- DKK 18,713,061
- Total Assets
- DKK 39,006,202
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 16 mio. | 4.5 mio. | 18.7 mio. | 4 |
| 2023 | - | 8.1 mio. | 461 t. | 14.3 mio. | 5 |
| 2022 | - | 2.9 mio. | -1.8 mio. | 13.8 mio. | 4 |
| 2021 | - | 14.5 mio. | 7.2 mio. | 13.2 mio. | 3 |
| 2020 | - | 15.2 mio. | 6 mio. | 12.9 mio. | 3 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
XGX Pharma ApS has won the tender "Amgros 2025 2.1310.b" issued by Amgros I/S worth 129,999,998 DKK.
XGX Pharma ApS has won the tender "Amgros 2025 1.1202.a" issued by Amgros I/S worth 90,124,932 DKK.
On August 6, 2024, the company changed its name from VITAL PHARMA NORDIC ApS to XGX Pharma ApS.
XGX Pharma ApS has published its annual report for 2023. Gross profit came to DKK 8,100,823, and the net result was DKK 460,891.
About XGX Pharma ApS
XGX Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named VITAL PHARMA NORDIC ApS and VITAL PHARMA NORDIC HOLDING ApS. The management consists of Jens-Nikolaj Schøier. The board consists of Per Anders Larnholt (chair) and Johan Frödin. The company is owned by Unimedic Pharma AB. The company has 6 employees (2026). In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. Equity in the 2025 report amounted to DKK 30,787,180.